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licenses/by-nc-nd/4.0/).AIM: To investigate the potential of iodine concentration (IC) determined using virtual
monochromatic spectral computed tomography (CT) to predict the response of gastric carci-
nomas to preoperative neoadjuvant chemotherapy (NC).
MATERIALS AND METHODS: A total of 20 patients were enrolled who underwent two
spectral CT examinations (1 week before and two cycles after NC). The percentage change in
tumour thickness (%DCWT) and in IC on the arterial phase (%DIC-a) and venous phase (%DIC-v)
after NC were calculated and compared for different histopathological regression grades and
response groups. The diagnostic efﬁcacies to discriminate good response (GR) and poor
response (PR) of the above three parameters were evaluated using receiver operating char-
acteristic (ROC) curves.
RESULTS: The decrease rate of %DIC-a for the GR group was higher than that for the PR group
(0.59 [0.76, 0.20] versus 0.11 [0.75, 0.92], p¼0.012). There was no signiﬁcant difference
in the %DIC-v and %DCWT values between the GR and PR groups (p¼0.076 and p¼0.779,
respectively). The areas under the ROC curve (AUC) values were 0.857, 0.762, and 0.542 for %
DIC-a, %DIC-v, and %DCWT, respectively, in the response prediction. The cut-off value for
identifying PR was a decrease rate of <52.9% for %DIC-a, and the sensitivity and speciﬁcity
values were 0.857 and 0.833.
CONCLUSION: Changes in the IC for gastric carcinomas following NC were detected using
spectral CT and correlated with histopathological regression. The prediction efﬁcacy for IC was
better than that for tumour thickness, with IC on the arterial phase being a better predictor
than IC on the venous phase.
 2015 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).n, No. 52 Fu Cheng Road, Hai Dian District, Beijing 100142, China. Tel./fax: þ86 10 88196822.
sunysabc@163.com (Y.-S. Sun).
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Preoperative neoadjuvant chemotherapy (NC) has been
successfully applied to the treatment of locally advanced
gastric carcinomas.1e3 For patients who responded well to
NC, prolonged survival times were observed compared with
non-responsive patients.1 In general, the potential beneﬁts
of NC include a reduction in tumour volume and a decrease
in tumour staging for primary and metastatic lesions,
micro-metastases can be treated earlier in a therapy course,
and the rate of radical resections is higher.1e3
Timely and accurate response evaluations of gastric car-
cinomas to NC can beneﬁt surgical decisions and can also
facilitate determinations of post-operation chemotherapy
regimens.2,3 Computed tomography (CT) is a commonly
used technique for evaluating the response of gastric car-
cinomas to chemotherapy, with tumour size reduction used
to evaluate therapeutic response based on Response Eval-
uation Criteria in Solid Tumours (RECIST) criteria4; how-
ever, the primary lesion of gastric carcinoma is generally not
considered a suitable target, due to its unﬁxed shape in the
hollow viscera, which prevents the collection of stable and
reproducible measurements of the longest tumour
diameter.5
Virtual monochromatic spectral CT represents an
important milestone in the development of CT technology.
It overcomes beam hardening that can occur with X-rays
and generates virtual-element CT images through material
decomposition. As a result, quantitative measurements of
element density (mg/ml), such as iodine concentrations
(ICs), can be performed.6 Post-enhancement ICs can reﬂect
changes in the blood supply in response to the biological
behaviour of tumours, and it has been hypothesised that
these changes can be used to evaluate tumour response to
anticancer therapies.7e10 The correlation between ICs
measured using spectral CT and the response of malignant
tumours to anticancer therapies has also been investigated,
and this has included studies of hepatocellular carcinomas
(HCCs),7,8 gastrointestinal stromal tumours,9 and non-
small-cell lung carcinomas.10 The hypothesis of the pre-
sent study was that the detection of iodine concentrations
by spectral CT can be used to evaluate the response of
gastric carcinomas to preoperative NC, and these data will
also be compared with histopathological results.Materials and methods
Patients
This prospective study was performed using an institu-
tional review board-approved protocol. Written informed
consent was obtained from all patients. The inclusion
criteria were as follows: (a) endoscopic histologically
conﬁrmed gastric carcinoma; (b) cT3 or cT4a carcinomas
based on CT and endoscopic ultrasonography; (c) a pre-
liminary diagnosis of gastric carcinoma without previous
chemotherapy; (d) no contraindications to enhanced CT
examination; (e) radical resection and standard NC beforesurgery; and (f) good compliance and willingness to un-
dergo enhanced CT examinations 1 week before, and two
cycles (3 days) after, the start of chemotherapy.
Conversely, the exclusion criteria were as follows: (a) the
time or amount of standard NC needed could not be
completed; (b) radical resection could not be performed
after chemotherapy; (c) CT examinations could not be per-
formed during the speciﬁed period of time; (d) poor gastric
lumen ﬁlling during CT examinations; or (e) there was no
difference in the thicknesses of the carcinoma and normal
gastric wall.
A total of 31 patients were enrolled before receiving
chemotherapy. Of these, 11 patients were excluded due to
the above criteria, with two patients not completing a
standard NC regimen, six patients not undergoing CT ex-
aminations within the arranged time period (one patient
underwent NC 1 month after completing a baseline CT ex-
amination, ﬁve patients did not undergo a follow-up CT
examination at the authors’ institution), and three patients
not undergoing radical excision (one patient refused the
operation because their symptoms were signiﬁcantly
relieved after NC, one patient needed medical treatment
due to signiﬁcant tumour progress, and one patient had
diffuse metastasis in their abdominal cavity discovered
during intraoperative exploration). Therefore, a total of 20
patients were enrolled in the present study, 12 men and
eight women (age range 35e73 years; median: 52 years).
CT examination
Phantom test
Phantom scanning was performed to verify the accuracy
of the ICs measured by spectral CT. Phantom scanning was
also used to perform calibration and quality assessments
prior to conducting studies on a Discovery CT750 HD sys-
tem (GE Medical Systems, Milwaukee, WI, USA). Eight
iodine solutions were prepared with various densities (0.2,
0.5, 1, 2, 5, 10, 20, and 30 mg/ml) and were transferred into
eight test tubes (each having a diameter of 2 cm). These
tubes were placed on an equally spaced model bracket for
VMS-CT examination. Imaging parameters for spectral CT
examinations included: spectral imaging mode with fast
tube voltage switching between 80 kVp and 140 kVp during
a single rotation, a tube current of 640 mA (the duration of
data acquisition for any given detection view was auto-
matically optimised to provide similar signal strength for
both voltages), 5 mm collimation thickness, 0.625 mm
reconstruction thickness, 0.6 seconds rotation speed, 0.984
helical pitch, and 22.82 mGy CT dose index volume (com-
parable to 25.17 mGy by conventional polychromatic CT
during gastric carcinoma imaging for an average-sized pa-
tient). Raw data were transferred to a commercially avail-
able workstation (AW4.4; GE Medical Systems), to generate
iodine-based material decomposition images. A radiologist
(Z.L.W.) placed circular regions of interest (ROIs) with the
same area on cross-sections of these test tube images to
cover as large an area as possible to obtain IC values. These
IC values were measured by VMS-CT and were compared
with the true ICs to calculate measurement errors (Table 1).
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Enrolled patients underwent spectral CT (Discovery
CT750 HD scanner, GE Medical Systems) examinations with
an empty gastrointestinal tract following overnight fasting.
If no contraindications were present (glaucoma, prostate
hypertrophy, asthma, or severe heart disease), 20 mg ani-
sodamine (Minsheng Pharmaceutical Group Company,
Hangzhou, China) was administered intramuscularly to
reduce gastrointestinal motility 15e20 min prior to CT ex-
amination. All patients of the present cohort received this
injection. All patients received effervescent granules (6 g) to
distend the stomach, and thenwere immediately instructed
to lie down on the scanning table in a supine position.
All patients underwent unenhanced and two-phase
enhanced CT examinations (arterial phase: 40 seconds af-
ter injection and venous phase: 70 seconds after injection).
These examinations were performed 1 week before NC and
after two cycles of NC. Each scan included the region from
the diaphragmatic dome to the bifurcation of the abdominal
aorta. Non-ionic contrast material (300 mg iodine/ml
iohexol, 1.5 ml/kg body weight, 80e120 ml total; Omnipa-
que, GE Healthcare) was injected through the antecubital
vein at a rate of 3.5 ml/s using an automatic power injector.
Patients were instructed to suspend respiration during
scanning, which was at the same level among the different
phases.
CT images were reconstructed using software designed
to decompose projection-based images. An adaptive sta-
tistical iterative reconstruction (ASIR, index ¼ 30%) algo-
rithmwas applied to suppress image noise and decrease the
radiation dose on spectral CT.Image analysis
Raw data were transferred to a commercially available
workstation (AW4.4, GEMedical Systems) and iodine-based
material decomposition images were generated. CT images
across all time points were analysed by two experienced
radiologists (Y.S.S. and L.T., with 16 and 12 years of experi-
ence with clinical CT, respectively) who were blinded to the
therapeutic responses. Measurements were made within 3
days of examination and consensus was reached between
the two radiologists.Table 1
Comparison between actual iodine concentrations and iodine concentrations
measured by spectral CT in the initial phantom experiment.
Actual iodine
concentrations (mg/ml)
Iodine concentrations
measured by CT (mg/ml)
Relative error
30 30.19 0.006
20 20.02 0.001
10 9.96 0.004
5 5.12 0.024
2 1.96 0.020
1 1.04 0.040
0.5 0.48 0.040
0.2 0.19 0.050A circular or elliptic ROI was drawn on the iodine-based
material decomposition images to include as much of the
highly enhanced portion of the largest lesion as possible
(mean number of pixels, 75; range, 20e200 pixels). Tumour
IC was recorded. All measurements were performed three
times, and the average values were calculated. ICs in the
arterial phase (IC-a) and the venous phase (IC-v) were
measured separately. Consistency in the position, shape,
and size of the ROIs drawn for the two phases was ensured
using a copy-and-paste method. Locations were measured
before and after NC and were kept as consistent as possible.
Areas containing prominent artefacts were carefully
avoided.
The percentage changes in IC values after NC were
calculated using the formula:
%DIC ¼ (ICafter  ICbefore)/ICbefore  100%.
By keeping distention levels and measurement positions
between pre- and post-therapy examinations consistent,
cancerous wall thickness (CWT) was measured using a
perpendicular axis to thewall, and the CWT regression rates
were calculated as follows:
%DCWT ¼ (CWTafter  CWTbefore)/CWTbefore  100%.
All of the enrolled patients underwent two cycles of
chemotherapy (S-1 and oxaliplatin [SOx] regimen) and
radical gastrectomy (performed by J.F.J. and Z.Y.L.). The
entire macroscopically identiﬁable carcinoma, or the area of
the stomach with scarring that indicated the site of the
previous tumour, was cross-sectioned serially at 0.2 cm
intervals. These tissue sections were stained with haema-
toxylin and eosin. A pathologist (Z.W.L.) evaluated and
recorded the gastric carcinoma regression scores. Grading
of tumour regression in response to chemotherapy was
based on an estimation of the percentage of vital tumour
tissue in relation to the macroscopically identiﬁable tumour
bed that was histologically evaluated. Carcinoma regression
grades were deﬁned as: Grade 1, complete or subtotal
regression (<10% residual tumour per tumour bed; Grade
1a indicated complete regression and Grade 1b indicated
subtotal regression); Grade 2, partial tumour regression
(10e50% residual tumour per tumour bed); and Grade 3,
minimal or no tumour regression (>50% residual tumour
per tumour bed).11 Grade 1 cases were further assigned to a
good responder group (GR), while Grade 2 and 3 cases were
assigned to a poor responder group (PR), according to a
previous positron-emission tomography (PET) study.5Statistical analysis
The pre-therapy quantitative indicators IC-a, IC-v, and
CWT, and their rates of change (%D), were compared by one-
way analysis of variance (ANOVA) for the different patho-
logical regression groups. These indicators were also ana-
lysed using non-parametric ManneWhitney U-tests
between the two response groups. Receiver operating
characteristic (ROC) curves were employed to evaluate the
Table 2
Comparison of quantitative parameters for different pathological regression grades.
Grade 1 (n¼6) median [min, max] Grade 2 (n¼8) median [min, max] Grade 3 (n¼6) median [min, max] Fa p-Valuea
IC-a 2.22 [1.37, 2.95] 2.77 [0.52, 3.50] 2.13 [0.86, 3.51] 0.016 0.984
IC-v 2.70 [2.24, 3.04] 3.06 [0.75, 4.89] 3.01 [2.13, 3.61] 0.209 0.814
CWT 14 [10, 28] 13 [10, 26] 15 [12, 24] 0.117 0.891
%DIC-a 0.59 [0.76, 0.20] 0.15 [0.62, 0.01] 0.10 [0.75, 0.92] 4.931 0.020b
%DIC-v 0.45 [0.66, 0.30] 0.30 [0.69, 0.05] 0.05 [0.62, 0.13] 3.993 0.038b
%DCWT 0.16 [0.65, 0.20] 0.01 [0.40, 0.08] 0.17 [0.33, 0.13] 0.458 0.640
IC-a: pre-therapy iodine concentrations for carcinomas during the arterial phase (mg/ml), IC-v: pre-therapy iodine concentrations for carcinomas during the
venous phase (mg/ml), CWT: pre-therapy carcinoma wall thickness (mm), %D: percentage change in quantitative parameters.
a p-Values determined with one-way analysis of variance.
b p < 0.05.
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dicators for a preoperative prediction of pathological
regression of gastric carcinoma after NC and to determine
cut-off values. p<0.05 was considered statistically
signiﬁcant.
Results
Phantom study
The values of actual ICs and ICs measured by spectral CT
in the phantom experiment are listed in Table 1. Relative
error values across the range of ICs were <5%.
Evaluation of gastric carcinoma response to NC
For the 20 patients enrolled in the study, carcinomas
were present at the cardiacefundus region (n¼6), gastric
body (n¼3), and gastric antrum (n¼11). Surgical histopa-
thology conﬁrmed 11 cases of poorly differentiated adeno-
carcinoma, four cases of moderately poorly differentiated
adenocarcinoma, four cases of moderately differentiated
adenocarcinoma, and one case of signet ring cell carcinoma.
Tumour staging included pT0 (n¼1), pT1b (n¼2), pT2 (n¼2),
pT3 (n¼11), pT4a (n¼3), and pT4b (pancreas invasion, n¼1);
as well as pN0 (n¼10), pN1 (n¼4), pN2 (n¼3), and pN3
(n¼3). Pre-therapy CWTs were all >10 mm, and the values
ranged from 12e28 mm (mean 16 mm).
There were six Grade 1 cases (including one Grade1a
case and ﬁve Grade 1b cases), eight Grade 2 cases, and six
Grade 3 cases. The distribution of pre-therapy absolute
values and post-therapy change rates for the quantitativeTable 3
Comparison of quantitative parameters between the different response groups.
Parameters GR (n¼6) median [min, max] PR (n¼
IC-a 2.22 [1.37, 2.95] 2.69 [
IC-v 2.70 [2.24, 3.04] 3.06 [
CWT 14 [10, 28] 15 [10
%DIC-a 0.59 [0.76, 0.20] 0.11
%DIC-v 0.45 [0.66, 0.30] 0.18
%DCWT 0.16 [0.65, 0.20] 0.04
IC-a: pre-therapy iodine concentrations for carcinomas during the arterial phase
venous phase (mg/ml), CWT: pre-therapy carcinoma wall thickness (mm), %D: p
a p-Values determined with ManneWhitney U-tests.
b p<0.05.parameters among the different pathological regression
grades are listed in Table 2. Only %DIC-a and %DIC-v
exhibited statistically signiﬁcant differences among the
pathological regression grades evaluated.
Patients with<10% residual tumour were assigned to the
GR group (n¼6), while patients with >10% residual tumour
were assigned to the PR group (n¼14). The rates of %DIC-a
and %DIC-v exhibited a greater decrease for the GR group
than for the PR group. Moreover, the difference in %DIC-a
was signiﬁcant (p¼0.012), whereas the difference in %DIC-v
was not (p¼0.076). The decreased rate for %DCWT was also
not statistically signiﬁcant between the GR and PR groups
(p¼0.779; Table 3, Fig 1).
Using ROC curves (Fig 2), the AUC values obtained were
0.857 (95% conﬁdence interval [CI]: 0.690 to 1.000), 0.762
(95% CI: 0.552 to 0.972), and 0.542 (95% CI: 0.208 to 0.875)
for %DIC-a, %DIC-v, and %DCWT, respectively, for response
predictions of gastric carcinoma to NC. The decreased rate
observed for IC-a demonstrated the best efﬁcacy of the
response judgments (Figs 3e4). Moreover, by selecting DIC-
a <52.9% as the cut-off value for identifying poor re-
sponders, the associated sensitivity and speciﬁcity values
were 0.857 (95% CI: 0.562 to 0.975) and 0.833 (95% CI: 0.365
to 0.991), respectively. When a decrease rate for DIC-v
<27.1% was selected as a cut-off value to judge poor re-
sponders, the associated sensitivity and speciﬁcity values
were 0.643 (95% CI: 0.356 to 0.86) and 1 (95% CI: 0.517 to 1),
respectively. When a decrease rate of %DCWT <17.4% was
selected as the cut-off value to judge poor responders, the
associated sensitivity and speciﬁcity values were 0.643 (95%
CI: 0.356 to 0.86) and 0.5 (95% CI: 0.14 to 0.861),
respectively.14) median [min, max] Z-Valuea p-Valuea
0.52, 3.51] 0.247 0.841
0.75, 4.89] 0.990 0.353
, 26] 0.042 0.968
[0.75, 0.92] 2.474 0.012b
[0.69, 0.13] 1.815 0.076
[0.40, 0.13] 0.290 0.779
(mg/ml), IC-v: pre-therapy iodine concentrations for carcinomas during the
ercent change in quantitative parameters.
Figure 1 Box plot showing the percent change in CWT, IC-a, and IC-v
values (%DCWT, %DIC-a, %DIC-v, respectively) for the GR and PR
groups of gastric carcinoma patients treated with two cycles of NC.
The horizontal lines represent the median value for each parameter.
The largest difference was observed for %DIC-a.
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Recently, several randomised Phase 3 studies have been
conducted with advanced gastric carcinoma patients, and
survival beneﬁts derived from preoperative NC versus direct
surgery were observed.3,12 Personalised preoperative
chemotherapy regimens for gastric carcinoma require sta-
ble, reproducible, and economical modalities for response
evaluations; however, commonly used RECIST criteria have
been associated with signiﬁcant deﬁciencies when used for
clinical response evaluations of gastric carcinomas.4,5Figure 2 ROC curves to evaluate the efﬁcacy of the percentage
change values for CWT, IC-a, and IC-v in the evaluation of gastric
carcinoma response after two cycles of NC. The order was %DIC-a > %
DIC-v > %DCWT.Spectral CT is a newly developed technique that provides
a potential solution for this problem. Spectral CT using a
rapid kilovoltage switching technique provides mono-
chromatic images of tissues that are similar to those ob-
tained with an X-ray source and single-energy X-ray
photons.13e16 Subsequent elemental decomposition ana-
lyses can be performed to obtain iodinated attenuation
maps, thereby allowing iodine density to be calculated so
radiologists can address diagnostic problems.6,17,18 In the
present study, ICs were initially measured in a phantom
experiment and the relative error rate was only 2% across
commonly enhanced soft tissues. Thus, the consistency
between spectral CT-measured ICs and the actual ICs was
relatively high. These results demonstrate the reproduc-
ibility of the present study.
Previously, ICs on CT were used to assess the response of
HCC to radiofrequency ablation,7 the responses of gastro-
intestinal stromal tumour (GIST)9 and HCC8 to targeted
therapy, and the response of non-small-cell lung carcinoma
to anti-angiogenic agents.10 The results of these studies
support the potential value of using ICs to evaluate tumour
response to various anticancer therapies. An additional
study suggested that detection of ICs may be a more robust
response parameter than the Choi criteria.9
The response of gastric carcinomas to chemotherapy has
been found to correlate closely with the destruction of
microvessel networks.19,20 Cytotoxic chemotherapeutic
agents can damage tumour cells and vascular endothelial
cells, thereby decreasing the capacity of the vascular bed
and reducing the blood content in tissues.19,20 Under such
conditions, an injection of iodinated contrastmedia exhibits
decreased distribution through the blood vessels.21 In the
present study, the change rates of ICs were calculated using
a material decomposition technique. A signiﬁcant correla-
tion between the change rates of IC and pathological
regression was observed. This may be used to reﬂect the
presence of the tumour cell remnants, and indicates the
potential for IC to be used as a functional biomarker for
evaluating the response of primary gastric carcinomas to
chemotherapy.
In the present study, both IC-a and IC-v were found to be
superior to tumour thickness regarding response predic-
tion. Sensitivity and speciﬁcity values for IC-a in the dif-
ferentiation of pathological regression were both above
80%. In comparison, the speciﬁcity for IC-v reached 100%,
while the sensitivity was only 64.3%. The ICs in both phases
outperformed tumour thickness in predicting pathological
regression. Meanwhile, the cut-off values for the assess-
ment of IC on arterial and venous phases were 50% and 30%,
respectively, which were signiﬁcantly higher than the 2%
error measured in the initial phantom study. It is predicted
that these cut-off values can be consistently applied in
clinical practice.
An interesting ﬁnding was that the performance of IC-a
was better than that of IC-v. IC-a mainly reﬂects capillary
density and the blood supply of gastric carcinomas, whereas
IC-v is a confounder that reﬂects the balance of blood
supply and the late-phase retention of contrast agent in
interstitial spaces. It has been demonstrated that gastric
Figure 3 Detection of IC for a good responder case. Conventional CT images are shown with the corresponding iodine-based material
decomposition images in the lower right corner of each panel. Images were obtained on the arterial phase before (a) and after (b) NC. The IC
values were 1.5 and 0.68 mg/ml, respectively. The %DIC-a was 54.7%. Images were also obtained on the venous phase before (c) and after (d) NC.
The IC values were 2.68 and 1.88 mg/ml, respectively. The %DIC-v was 29.9%. (e) Haematoxylin/eosin staining of a pathological section obtained
from radical resection that was graded as 1b regression.
Figure 4 Detection of IC for a poor responder case. Conventional CT images are shown with the corresponding iodine-based material
decomposition images in the lower right corner of each panel. Images were obtained on the arterial phase before (a) and after (b) NC. The IC
values were 1.56 and 2.99 mg/ml, respectively. The %DIC-a was 91.7%. Images were also obtained on the venous phase before (c) and after (d) NC.
The IC values were 2.57 and 2.90 mg/ml, respectively. The %DIC-v was 12.8%. (e) Haematoxylin/eosin staining of a pathological section obtained
from radical resection that displayed Grade 3 regression.
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during the venous phase, and this is highly dependent on
the desmoplastic response.22 Furthermore, ﬁbrosis can
obstruct the clearance of the contrast agent, thereby leading
to a continuous increase in IC values. When evaluating
pathologicaleradiological correlations, it was observed that
the degree of ﬁbrosis may not decrease proportionally with
destruction of tumour cellularity following chemotherapy,
and may become aggravated as a result of carcinoma tissue
degeneration.23 This obstruction effect may counterbalance
the decrease in blood supply and cause a slight decrease in
ICs during the venous phase of GR lesions. Thus, the above
hypothesis may account for the lower efﬁcacy of IC-v in the
response evaluation. The 50% cut-off value for IC-a was also
signiﬁcantly higher than the 30% cut-off value for IC-v, and
this may highlight the differences between various
response groups.
There were some potential limitations of the present
study. First, being a pilot feasibility study, only a small
cohort of 20 patients was enrolled. Therefore, a larger pro-
spective investigation is needed to conﬁrm the present
ﬁndings. This is especially true for the determination of the
threshold for clinical practices. Second, the corresponding
histopathological explanations represent preliminary
speculations based on available literature and general ob-
servations. Therefore, further experiments are needed to
conﬁrm these potential correlations. Third, due to an
inherent limitation of the software used, only round or oval-
shaped ROIs could be used. If outline curves could be
applied to the entire carcinoma area, the results may be
more objective and may comprehensively reﬂect the bio-
logical behaviour; however, as large necrotic areas are rare
in gastric carcinomas treated with chemotherapy, the esti-
mated inﬂuence is relatively slight. Finally, although the aim
of the study was to evaluate the primary tumour, further
study should be designed to evaluate metastatic lymph
nodes, another independent prognostic factor for gastric
cancer.
In conclusion, changes in ICs measured by spectral CT in
gastric carcinomas after neoadjuvant chemotherapy corre-
late well with pathological regression. The predicted efﬁ-
cacy of ICs on spectral CT is better than tumour thickness,
and ICs on the arterial phase are more predictive than on
the venous phase.
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